





Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate *N*-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development

Jordi Chi,^a Marta Cova,^a Matilde de las Rivas,^b Ana Medina,^c Rafael Junqueira Borges,^{c,d} Pablo Leivar,^e Antoni Planas,^e Isabel Usón,^{c,f}  Ramón Hurtado-Guerrero,^{b,g,h,i}  Luis Izquierdo^a

^aISGlobal, HospitalClinic–Universitat de Barcelona, Barcelona, Spain

^bInstitute of Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Zaragoza, Spain

^cCrystallographic Methods, Institute of Molecular Biology of Barcelona (IBMB–CSIC), Barcelona, Spain

^dDepartamento de Física e Biofísica, Instituto de Biociências, Universidade Estadual Paulista (UNESP), Botucatu, Brazil

^eLaboratory of Biochemistry, Institut Químic de Sarrià, Universitat Ramon Llull, Barcelona, Spain

^fICREA, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain

^gCopenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, School of Dentistry, University of Copenhagen, Copenhagen, Denmark

^hLaboratorio de Microscopías Avanzada (LMA), University of Zaragoza, Zaragoza, Spain

ⁱFundación ARAID, Zaragoza, Spain

Jordi Chi and Marta Cova contributed equally to this work. Author order was determined alphabetically.

ABSTRACT UDP-*N*-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and *N*- and *O*-linked glycans. Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate *N*-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s. By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual *Plasmodium falciparum* parasites. Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from *Cryptosporidium parvum*, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for *P. falciparum* GNA1. The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants. The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway. This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.

IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy. The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites. We demonstrate that glucosamine-6-phosphate *N*-acetyltransferase (GNA1), required for the biosynthesis of UDP-*N*-acetylglucosamine (UDP-GlcNAc), is essential for *P. falciparum* asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle. The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite *C. parvum*, used here as a surrogate, highlights significant differences from human GNA1. These divergences can be exploited for the design of specific inhibitors against the malaria parasite.

Citation Chi J, Cova M, de las Rivas M, Medina A, Borges RJ, Leivar P, Planas A, Usón I, Hurtado-Guerrero R, Izquierdo L. 2020. *Plasmodium falciparum* apicomplexan-specific glucosamine-6-phosphate *N*-acetyltransferase is key for amino sugar metabolism and asexual blood stage development. *mBio* 11:e02045-20. <https://doi.org/10.1128/mBio.02045-20>.

Editor Dominique Soldati-Favre, University of Geneva

Copyright © 2020 Chi et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Ramón Hurtado-Guerrero, rhurtado@bifi.es, or Luis Izquierdo, luis.izquierdo@isglobal.org.

Received 27 July 2020

Accepted 18 September 2020

Published 20 October 2020

KEYWORDS malaria, metabolism, *Plasmodium falciparum*, UDP-*N*-acetylglucosamine, aminosugar pathway, apicomplexan parasites

In 2018 there were more than 200 million clinical cases of malaria, a parasitic disease caused by species of the genus *Plasmodium*, that led to more than 400,000 deaths. Most of them were caused by *Plasmodium falciparum* parasites in children under 5 years old in Sub-Saharan Africa (1). Despite the strong calls for malaria elimination and the important advances made in this direction since the beginning of the 21st century, recent reports indicate the lack of significant progress in reducing global malaria cases in the last few years (1, 2). This slowdown, together with the recent emergence of resistance to first-line antimalarial treatments (3, 4), poses an imminent threat that endangers the outstanding improvements against the disease made in the last decades. Therefore, new approaches to control malaria, including the characterization of essential metabolic pathways and drug targets and the development of new chemotherapeutic treatments, are urgently needed (5, 6).

Malaria infection begins with the inoculation of *P. falciparum* sporozoites into the human dermis through the bite of a parasite-infected female *Anopheles* mosquito. Sporozoites enter the bloodstream and reach the liver, where they invade and develop inside hepatocytes, giving rise to exoerythrocytic merozoites. Released merozoites then invade red blood cells (RBCs) and initiate multiple ~48-h rounds of asexual replication, leading to an exponential parasite growth which is responsible for disease symptoms (7). A small fraction of blood stage parasites, about 1 to 2%, differentiate into sexual forms and produce male and female gametocytes, transmissible to *Anopheles* mosquitoes during a blood meal. Once inside the mosquito midgut, gametocytes form male and female gametes that undergo sexual recombination to produce ookinetes and then oocysts, which end up releasing new sporozoites. Therefore, antimalarial drugs should not only eliminate asexual blood stage parasites, but also target preerythrocytic and sexual stages to prevent and block disease transmission, contributing to malaria elimination strategies (4, 8).

Recent works highlight the importance of the amino sugar pathway and its final product, the sugar nucleotide UDP-*N*-acetylglucosamine (UDP-GlcNAc), for the survival of human and murine malaria parasites along different life stages (9–12). Sugar nucleotides are activated sugar precursors used by glycosyltransferases to produce glycoconjugates, and UDP-GlcNAc is required for the biosynthesis of glycosylphosphatidylinositol (GPI) anchors and *N*-glycans (13). These glycoconjugates play essential roles in *P. falciparum* (14, 15) and other protozoan parasites (16, 17). Malaria parasites present a conventional amino sugar metabolic route for the synthesis of UDP-GlcNAc (18) with the particularity that the glucosamine-6-phosphate *N*-acetyltransferase (GNA1) enzyme belongs to an apicomplexan-specific gene family with unique sequence features and conserved motifs (10). These specificities might render GNA1 amenable for selective inhibition. In this work, we demonstrate the importance of the enzyme for the biosynthesis of UDP-GlcNAc and the survival of the parasite along its intraerythrocytic life cycle, outlining the distinctive features of apicomplexan GNA1s by reporting the crystal structure of the *C. parvum* homologous GNA1 enzyme.

RESULTS

Conditional disruption of the *gna1* gene in *P. falciparum*. Previous work showed the *P. falciparum gna1* gene could not be ablated but its coding sequence could be engineered to include synonymous substitutions, strongly suggesting an indispensable role for asexual intraerythrocytic parasites (10). Thus, to gain further insights into the importance of the gene for *P. falciparum* asexual blood stage development, we engineered a *gna1* conditional null mutant using a rapamycin-inducible dimerizable Cre-recombinase (DiCre) system (19). By CRISPR-Cas9 technology (20), we introduced two *loxP* sites in the gene, one in a synthetic intron (21) within the *gna1* open reading frame, and another in the 3' untranslated region (Fig. 1A). DiCre-




FIG 1 Conditional disruption of *P. falciparum gna1* gene. (A) *P. falciparum gna1* is a single-exon gene. Using Cas9-assisted genome editing, 696 bp of the native *gna1* open reading frame were replaced with a *loxP* (purple open arrowhead)-containing intron (orange line), and an additional *loxP* site that flanks a recodonized version of *P. falciparum gna1*. Integration of this sequence by double crossover homologous recombination was promoted by (i) Cas9 endonuclease-mediated double-strand DNA breaks, guided by a single guide RNA (sgRNA) targeting a 20-nucleotide region of *PfGNA1* (green arrows); and (ii) the addition of homologous sequences (red box at the 5' region and thick red line at the 3' region) to either side of the *loxP* sites. Closed colored arrows indicate the primer binding sites. Rapamycin-induced site-specific recombination between the *loxP* sites removes the recodonized part of the gene (green box) encompassing 223 amino acids of the 291 amino acids of the *PfGNA1* enzyme. (B) PCR analysis of *gna1-loxP* clones C4 and G8 confirms successful gene editing. Genomic DNA from parental 3D7 (WT) parasites or C4 and G8 clones was used as the template for PCR using the primers indicated in panel A. The numbers between the colored arrows indicate the expected amplicon size. (C) Truncation of the rapamycin-induced *gna1* gene. *gna1-loxP* C4 and G8 clones were analyzed by PCR ~29 h after treatment with DMSO (D) or rapamycin (R) using the primers identified in panel A. Excision reduces the amplicon from 1,552 bp to 733 bp, disrupting *gna1*.

mediated excision of the floxed sequence could be induced by adding rapamycin into the media. The ablation disrupts a region comprising 669 bp of the *gna1* gene, including the Gcn5-related *N*-acetyltransferase (GNAT) domain, conserved in enzyme families that use acetyl-CoA to acetylate substrates (22, 23). The genomic modification was engineered in the DiCre-expressing *P. falciparum* line 3D7 II.3 (19).

Confirmation of the appropriate modification of the *gna1* gene after transfection was assessed by diagnostic PCR. Subsequent limiting dilution cloning of the *gna1* locus-modified parasites resulted in the isolation of *gna1-loxP*-C4 and *gna1-loxP*-G8 clones, in which the modification of the locus was reconfirmed again by PCR (Fig. 1B). Efficiency of the conditional excision of the floxed *gna1-loxP* clones was assessed by the addition of rapamycin or dimethyl sulfoxide (DMSO; vehicle control) in ring stage synchronized cultures. Cells were treated for 1 h, followed by washing and incubation for 29 h to allow parasite maturation. Genomic DNA from the clones was used for diagnostic PCR using primers annealing in the homology regions that demonstrated the efficient excision of *gna1-loxP* (Fig. 1C). Both clones were used in all subsequent experiments.




FIG 2 *P. falciparum gna1* disruption produces developmental arrest and reduces the UDP-GlcNAc pool. (A) Synchronous ring-stage *gna1-loxP* growth curves of C4 and G8 clones showing parasite replication over the course of three erythrocytic cycles when grown in the presence of DMSO, rapamycin, or rapamycin + 10 mM GlcNAc. Data were averaged from three biological replicates and presented as the mean \pm standard deviation (SD). (B) Invasion rates of DMSO- or rapamycin-treated cultures (clones C4 and G8). The graphs show mean \pm SD values of three replicates and significance was assessed using unpaired *t* tests. (C) Quantification of UDP-GlcNAc and other sugar nucleotide pools in late stages (mature trophozoites) of *gna1-loxP* parasites treated with rapamycin. Values indicate the sugar nucleotide concentration \pm SD of six different biological replicates. Unpaired *t* tests were used to compare differences; ***, $P < 0.05$; ns, not significant.

Disruption of the *gna1* gene leads to the inhibition of parasite growth and reduction of UDP-GlcNAc pools.

GNA1 catalyzes the acetylation of glucosamine-6-phosphate (GlcN6P) to generate *N*-acetylglucosamine-6-phosphate (GlcNAc6P), which is needed for the biosynthesis of UDP-GlcNAc, a required precursor for both GPI-anchors and *N*-glycans (10). These glycoconjugates are critical for parasite viability and, hence, a defect in their synthesis may largely affect *P. falciparum* development. To ascertain the effect of *gna1* loss in asexual parasites, rapamycin-treated cells were grown and monitored by flow cytometry over ~ 144 h (i.e., three intraerythrocytic developmental cycles [IDCs]). Upon rapamycin-induced *gna1-loxP* excision, parasites failed to expand over three IDCs, whereas DMSO-treated parasites grew normally. Neither rapamycin nor DMSO affect parasite growth at the incubation times and concentrations used (19). Interestingly, parasite growth in rapamycin-treated cultures was rescued by supplementing the medium with 10 mM GlcNAc, suggesting the presence of a metabolic pathway for the uptake and activation of free GlcNAc (Fig. 2A). Rapamycin-treated cultures showed an ~ 2.5 -fold invasion rate reduction in the first IDC, indicating the expansion of a small proportion of viable parasites that likely reflects the kinetics of DiCre-mediated excision (19), GNA1 turnover, and/or the dynamics of sugar nucleotide pools (24) (Fig. 2B). Nevertheless, invasion rates were reduced to 1 (i.e.,

absence of growth) in rapamycin-treated cultures at cycles 2 and 3. Parasite morphology along the IDCs was normal in DMSO treated-cultures, gradually losing synchronization after 2 to 3 cycles. In contrast, in rapamycin-treated cultures, growth-arrested parasites accumulated as trophozoites and schizonts, indicating that *gna1* is needed for parasite development through mature stages (Fig. S1 in the supplemental material). To precisely assess the effect of *PfGNA1* loss on UDP-GlcNAc levels, we measured and compared the sugar nucleotide dynamic pools of DMSO-treated parasites with those of rapamycin-treated parasites. Upon rapamycin treatment, the UDP-GlcNAc pool was significantly reduced, despite that levels of other sugar nucleotides remained similar (Fig. 2C). Therefore, without discarding potential *PfGNA1* moonlighting activities essential for parasite development, the results strongly suggest that *gna1* disruption prevents GlcN6P acetylation by *PfGNA1* and reduces the pool of UDP-GlcNAc, hindering *P. falciparum* asexual intraerythrocytic growth.

C. parvum GNA1 structural analysis. *PfGNA1* activity is crucial for the development of the malaria parasite and, therefore, understanding the structural differences with human GNA1 (*HsGNA1*) may contribute to the discovery of *PfGNA1*-selective inhibitors. To further characterize the enzyme and, given our inability to express and purify sufficient amounts of active *PfGNA1* (10), we used *CpGNA1* as a surrogate, considering that it belongs to the same Apicomplexa-specific GNA1 family and can be purified fairly well with a high yield (10). The percentage of pairwise identity within the ca. 90-amino acid conserved region of the *CpGNA1* and *PfGNA1* GNAT domains is 48.8% (similarity 61.9%). The first *CpGNA1* structure, determined from crystals belonging to the space group $P2_12_12_1$, with one monomer in the asymmetric unit, was solved by using the multiresolution parallel phasing software ARCIMBOLDO (25). Extension of the placed fragments with SEQUENCE SLIDER (26) was required. The dimeric structure of *CpGNA1* in complex with acetyl-CoA and glucose-6-phosphate (Glc6P) from data at 1.95 Å in space group $P2_12_12_1$ was solved by molecular replacement with Phaser (27) using the monomeric structure (Fig. 3A and B), and further assessing ligand binding by representing unbiased sim-omit maps (Fig. S2). Note that Glc6P was used previously as a pseudosubstrate to get insights into GNA1-GlcN6P recognition and catalysis (Fig. 3A and B) (28). *CpGNA1* is found as a dimer, as is the case for other reported GNA1 crystal structures (29–31). *CpGNA1* adopts the typical GCN5-related *N*-acetyltransferase (GNAT) fold previously described in GNA1 enzymes, though with some variations (see below; Fig. 3A) (29). The *CpGNA1* structure consists of a central twisted four-stranded antiparallel β -sheet surrounded by four α helices (Fig. 3A). This feature is conserved with *HsGNA1*, though this enzyme also contains additional β -strands and α -helices (Fig. 3C and Fig. S3) (32). The superposition of *CpGNA1* and *HsGNA1* monomers gives a root mean square deviation (RMSD) of 1.68 Å on 132 $C\alpha$ atoms, suggesting some conformational differences (Fig. 3C). Additionally, *HsGNA1* resembles the more typical signature of the GNAT superfamily than does *CpGNA1*, supporting our previous data that suggest an independent evolutionary origin and highlight the presence of significant differences between apicomplexan and nonapicomplexan GNA1s, as discussed in reference 10. Actually, the Apicomplexa GNA1 family shows a taxonomic distribution restricted to apicomplexan organisms (10). In agreement, the typical topology for GNAT-fold-adopting members ($\beta1-\alpha1-\alpha2-\beta2-\beta3-\beta4-\alpha3-\beta5-\alpha4-\beta6-\beta7$) (32–34) is more consistent with that found for *HsGNA1* ($\alpha1-\beta1-\alpha2-\alpha3-\beta2-\beta3-\alpha4-\beta4-\alpha5-\beta5-\alpha6-\beta6$) and more distant to that found for *CpGNA1* ($\beta1-\alpha1-\alpha2-\beta2-\beta3-\beta4-\alpha3-\alpha4$), which contains significantly fewer secondary structure elements (Fig. S3). Remarkably, the highly conserved tyrosine of the active site, also present in *CpGNA1* (Tyr127), establishes a hydrogen bond between its hydroxyl group and the thioester sulfur, leading to an increase in the electrophilic character of the carbonyl group of the acetyl-CoA molecule during catalysis (28, 30) (Fig. 3A). This is key for favoring a direct nucleophilic attack by the GlcN6P amine (28) that promotes catalysis. Note the proximity of the Glc6P OH₂ that mimics the amine group of GlcN6P to the carbonyl group of acetyl-CoA (distance




FIG 3 CpGNA1 and human HsGNA1 folding and conservation of the substrate-binding site. (A) Overall crystal structure of CpGNA1. Secondary structure is shown in blue (strands) and red (helices) for both monomers. The highly conserved active site tyrosine residue is shown as sticks with gray carbon atoms. Acetyl-CoA and Glc6P are shown as sticks with green carbon atoms. (B) Two different views of the electron density map $F_o - F_c$ (blue), which is contoured at 2.0σ for acetyl-CoA and glucose-6P. Note that the electron density is of good and moderate quality for acetyl-CoA and glucose-6P, respectively. (C) Superposition of the monomers from CpGNA1 (gray) and HsGNA1 (blue). The equivalent Tyr127 of CpGNA1 is Tyr165 in the HsGNA1 (shown as blue carbon atoms). (D) Surface representation (upper panel) of CpGNA1 and HsGNA1 structures colored in gray. Note the different shapes of the binding site between both enzymes and the differences of acetyl-CoA and CoA, which are mostly evidenced by large conformational changes between the adenine moieties (see the lower panel). (E) Surface representation of CpGNA1 in which the degree

(Continued on next page)




FIG 4 Multiple sequence alignment of *CpGNA1*, *HsGNA1*, and *PfGNA1*. The *CpGNA1* residues that interact with acetyl-CoA and Glc6P and the grade of conservation with other *CpGNA1* orthologs based on these interactions are highlighted as follows: yellow (full conservation); green (conserved residues between *CpGNA1* and *PfGNA1*); magenta (conserved residues between *CpGNA1* and the *HsGNA1*); and black/gray colors that indicate the degree of conservation between the three orthologs. Residues interacting with acetyl-CoA and Glc6P are also displayed as magenta diamonds and inverted orange triangles, respectively. Shown above the sequence for *CpGNA1*, in red and blue, is displayed the secondary structure elements (α -helices and β -strands, respectively). Note that residues 90 to 93 of *CpGNA1* align well at the structural level with the equivalent residues in *HsGNA1* but not at the sequence level. This is evidenced for *CpGNA1* Asn90 and *HsGNA1* Gln132, and *CpGNA1* Gly92 and *HsGNA1* Gly130. The four different motifs present in the GNAT family of higher eukaryotes are represented as open red boxes (32). The secondary structures are mostly conserved between *CpGNA1* and *HsGNA1* in motifs D and A, and to a lesser extent in motif B (see Fig. S3 for a comparison of the secondary structure elements between both enzymes), exemplifying the large differences between the enzymes from higher eukaryotes and the Apicomplexa phylum.

of 3.45 Å; Fig. 3B), which clearly supports that the same mechanism might take place for *CpGNA1*.

***CpGNA1* active site.** A close inspection of the active site of *CpGNA1* and its comparison with the *HsGNA1* active site showed that both the GlcN6P and the acetyl-CoA binding sites have different shapes (Fig. 3D), and are also different at the sequence level (Fig. 3E and Fig. 4). This is more evident for the acetyl-CoA binding site, in which significant differences in the acetyl-CoA/CoA phosphorylate ADP moiety are found. For example, the angle between both adenine moieties is close to perpendicular (74°) and the distance between the free amines is large (5.4 Å) (Fig. 3D). Note that the angle is formed between the C1B of the phosphorylated ribose and the two C4A of the adenine moieties. However, the *CpGNA1* active site and the predicted *PfGNA1* active

FIG 3 Legend (Continued)

of conservation of amino acid residues surrounding the binding site are color coded. *CpGNA1* was compared with *HsGNA1* (upper panel) and *PfGNA1* (lower panel). Note that no models were generated for either *HsGNA1* or *PfGNA1* and that the differences were exclusively based on amino acid sequence alignments. Orange and white represent identity/conservative substitutions and nonconservative substitutions, respectively. The ligands are represented as sticks with green carbon atoms, except for acetyl-CoA and glucose-6P in lower panel of (D), in which they are colored as brown carbon atoms.




FIG 5 Comparison of the *Cp*GNA1 and human *Hs*GNA1 active sites. Two different views are depicted for each active site to better visualize the interactions between the ligands and the amino acids. The protein backbone is shown as a gray ribbon. Ligands are shown as sticks with green carbon atoms. *Hs*GNA1 residues interacting with the ligands are shown for comparison and illustrative purposes but will not be discussed in detail. Protein–ligand hydrogen bonds are shown as dotted green lines. Identical, homologous, and dissimilar residues between both enzymes are colored in gray, black, and brown carbon atoms, respectively. Note that the superscript B in several residues defines residues that come from chain B.

site are more similar (Fig. 3B), as anticipated in our previous work (10). There are 19 residues of *Cp*GNA1 engaged in the recognition of acetyl-CoA and Glc6P (Fig. 4 and Fig. 5). Some of these residues forming the GlcN6P binding site come from both monomers (see Fig. 5). Out of these 19 residues, 11 residues are conserved between *Hs*GNA1 and *Cp*GNA1, whereas 15 residues are conserved between *Cp*GNA1 and *Pf*GNA1. Two residues are unique in *Cp*GNA1, though these residues interact with the ligands through their backbones (Fig. 4 and Fig. 5).

The adenine moiety and the dimethyl group of acetyl-CoA establish CH- π and CH-CH interactions with Ile122 and Ala123/Leu126, respectively. The phosphorylated ribose, pyrophosphate, pantothenic acid, the β -mercaptoethylamine, and the acetyl moieties are tethered via hydrogen bonds to the Arg95 side chain and Lys125 backbone, Asn90/Arg91/Gly92/Gly94/Arg95 backbones, Ile84 backbone, Val82 backbone, and His81/Val82 backbones, respectively (Fig. 5). The Glc6P is tethered via hydrogen bonds to the His81/Thr117/Arg27 backbones and Arg73^B/His81/Arg113^B/Thr117 side chains (Fig. 5). Note that the sugar moiety is also recognized by residues belonging to the chain B in both *Cp*GNA1 and *Hs*GNA1 (Fig. 5).

C. parvum GNA1 site-directed mutagenesis. Based on the structural information, nine *Cp*GNA1 site-specific mutants were created to study the contribution of specific residues to *Cp*GNA1 binding and activity. All mutants were designed to disrupt the binding of either acetyl-CoA (N90A, I122G, and Y127A) or GlcN6P (R73A, R141A, R113A, T117A, E119A, and H81A) (Fig. 5). Note that in our structure, the critical Tyr127 and Arg141 were very close to the ligands but did not show any interaction (Fig. 5).




FIG 6 *CpGNA1* kinetics. (A) *CpGNA1* steady-state velocities for recombinant WT *CpGNA1* (left panel) and *CpGNA1* mutants (right panel) using different concentrations of acetyl-CoA at a fixed (2,000 μM) concentration of GlcN6P. (B) *CpGNA1* steady-state velocities for recombinant WT *CpGNA1* (left panel) and *CpGNA1* mutants (right panel) using different concentrations of GlcN6P at a fixed (500 μM) concentration of acetyl-CoA.

However, and considering the importance of the Tyr counterparts in other orthologs (28), it would be expected that the mutation of Tyr127 to Ala would diminish or abolish the activity, as shown below. The selected amino acids were replaced by alanine (A) in all cases except for Ile122, for which isoleucine was replaced by glycine (I122G).

The steady-state kinetic parameters of wild type (WT) and *CpGNA1* mutants were studied by an *in vitro* colorimetric assay by monitoring CoA release, with increasing concentrations of acetyl-CoA at a fixed concentration of GlcN6P and vice versa (Fig. 6). The R73A, R113A, R141A, and Y127A activities were almost negligible, hampering the calculation of reliable kinetic parameters (Table 1).

CpGNA1 mutant kinetics data showed a general decrease in catalytic efficiency (k_{cat}/K_m) and enzyme maximal specific activity (defined here as V_{max}) (Table 1). The catalytic efficiency of *CpGNA1* mutants decreased between 2.6- and 5.2-fold and 18.6- to 1,754-fold for acetyl-CoA and GlcN6P, respectively. V_{max} also decreased between 8- and 83-fold, depending on the mutant enzyme. With respect to the K_m values, all mutants displayed lower values for acetyl-CoA, indicating a higher affinity for this substrate than WT *CpGNA1*. Regarding GlcN6P, all mutants displayed higher K_m values, suggesting a lower affinity for GlcN6P compared to WT. T117A showed the lowest K_m for acetyl-CoA ($K_m = 33.41 \pm 11.82 \mu\text{M}$, which is a 15.9-fold K_m decrease compared to

TABLE 1 Comparison of the kinetic parameters between WT and mutant *CpGNA1*

| Enzyme | Acetyl-CoA | | | | GlcN-6P | |
|----------------------|--|---|-------------------------|---|-------------------------|---|
| | V_{max} ($\mu\text{mol min}^{-1} \mu\text{g}^{-1}$) | k_{cat} (s^{-1}) ^a | K_m (μM) | k_{cat}/K_m ($\text{s}^{-1} \mu\text{M}^{-1}$) | K_m (μM) | k_{cat}/K_m ($\text{s}^{-1} \mu\text{M}^{-1}$) |
| <i>CpGNA1</i> -WT | 32.86 ± 0.78 | 10.31 | 531 ± 80.33 | $1.94 \times 10\text{E-}2$ | 153.9 ± 16.46 | $6.7 \times 10\text{E-}2$ |
| <i>CpGNA1</i> -N90A | 3.53 ± 0.06 | 1.10 | 252.4 ± 44.43 | $4.37 \times 10\text{E-}3$ | 532.7 ± 24.84 | $2.07 \times 10\text{E-}3$ |
| <i>CpGNA1</i> -E119A | 4.09 ± 0.19 | 1.28 | 170.4 ± 25.06 | $7.5 \times 10\text{E-}3$ | 1136 ± 125.2 | $1.13 \times 10\text{E-}3$ |
| <i>CpGNA1</i> -I122G | 3.99 ± 0.34 | 1.25 | 309.2 ± 54.94 | $4.03 \times 10\text{E-}3$ | 335.7 ± 33.78 | $3.71 \times 10\text{E-}3$ |
| <i>CpGNA1</i> -H81A | 1.07 ± 0.04 | 0.34 | 88.9 ± 10.98 | $3.77 \times 10\text{E-}3$ | 4007 ± 1425 | $8.36 \times 10\text{E-}5$ |
| <i>CpGNA1</i> -T117A | 0.4 ± 0.03 | 0.12 | 33.41 ± 11.82 | $3.73 \times 10\text{E-}3$ | 3245 ± 346.4 | $3.84 \times 10\text{E-}5$ |
| <i>CpGNA1</i> -R113A | ND | ND | ND | ND | ND | ND |
| <i>CpGNA1</i> -R73A | ND | ND | ND | ND | ND | ND |
| <i>CpGNA1</i> -R141A | ND | ND | ND | ND | ND | ND |
| <i>CpGNA1</i> -Y127A | ND | ND | ND | ND | ND | ND |

^a k_{cat} values were calculated using the molecular weight of the protein itself; the GST tag was not considered for the calculations since it does not affect *CpGNA1* activity. ND, not determined.

WT) and H81A the highest K_m for GlcN6P ($K_m = 4,007 \pm 1,425 \mu\text{M}$, which is a 26-fold K_m increase compared to WT). Nevertheless, T117A and H81A showed remarkably low catalytic efficiencies for both acetyl-CoA and GlcN6P. Although it was expected to see a weak affinity for GlcN6P in the T117A mutant, the higher affinity for acetyl-CoA was not predicted because Thr117 shows only interactions with the pseudosubstrate Glc6P (Fig. 5). The relevance of key residues for substrate interaction, especially those related to GlcN6P binding (i.e., Arg73, Arg113, and Thr117), which are not conserved in *HsGNA1*, strongly prompts further exploration of the enzyme as a selective drug target against *P. falciparum* and, possibly, other apicomplexan parasites. Overall, and except for Y127A, our results suggest that most of the mutants with alterations around the GlcN6P binding site show more significant effects on the kinetic properties under variable GlcN6P concentrations than the corresponding mutants show with acetyl-CoA. This implies a more significant role of the native residues around the GlcN6P binding site than the residues around acetyl-CoA.

DISCUSSION

In this work we use CRISPR-Cas9-based engineering techniques (20), combined with a DiCre-recombinase system, for conditional *P. falciparum gna1* gene disruption upon rapamycin induction (19, 21, 35). This is a widely used and versatile strategy for rapid conditional gene ablation and functional analysis of essential genes in the malaria parasite. The data demonstrate that *PfGNA1*, which acetylates GlcN6P in the amino sugar pathway, is required for the synthesis of adequate pools of UDP-GlcNAc and for parasite development during the asexual intraerythrocytic stages of the parasite. This confirms results from large-scale genetic screenings recently carried out in *P. falciparum*, underlining the relevance of the enzymes in the amino sugar pathway for the survival of asexual parasites (11). Remarkably, works performed in a *P. berghei* murine model of malaria also highlight the critical role of UDP-GlcNAc and the amino sugar metabolic route in mosquito and liver stages (12). However, contrasting to *P. falciparum* (11), *P. berghei* mutants in the UDP-GlcNAc biosynthetic route showed only slow-growth phenotypes in asexual intraerythrocytic parasites, indicating the nonessentiality of the pathway at these stages of the life cycle (12, 36). Despite that a *gna1* mutant has not been generated and UDP-GlcNAc levels have not been characterized in *P. berghei* (12, 36), this suggests that murine parasites can obtain UDP-GlcNAc from host cells or alternative sources along intraerythrocytic asexual development (12). Indeed, there exist other examples in which the alteration of a *de novo* sugar nucleotide metabolic route does not cause a significant reduction of the pathway's product (37), and our own data show that *P. falciparum gna1* mutant growth is rescued *in vitro* by GlcNAc medium supplementation. Thus, *P. falciparum* parasites seem to be able to take up and activate GlcNAc when the amino sugar pathway is disrupted (38), in agreement with the wide range of sugars that can be imported through its hexose transporter 1 (39). Nevertheless, *P. falciparum* potential GlcNAc uptake is deemed to be negligible *in vivo*, as this is not an abundant free sugar in the parasite host (40), opening the door to explore the selective inhibition of *PfGNA1* as a new approach to treat malaria.

To identify structural differences between *PfGNA1* and *HsGNA1* that could be exploited for selective drug design, we intended to solve the *P. falciparum* enzyme 3D structure. However, the deficient expression of *PfGNA1* prompted us to explore *CpGNA1* as a surrogate model for Apicomplexa-specific GNA1 (10). Fortunately, *CpGNA1* is expressed at high levels in *Escherichia coli*, allowing us to obtain structural and enzymatic insights. Remarkably, despite the low identity at sequence level between *CpGNA1* and *HsGNA1*, the crystal structures are similar and share the typical acetyltransferase fold (23). Although this had been already described in members of the GNAT superfamily, which show well-conserved structures and catalytic mechanisms despite extensive divergence at the sequence level (29, 32, 33), the independently evolved Apicomplexa GNA1 family still presents different catalytic residues crucial for enzymatic activity (10). Though both the *CpGNA1* acetyl-CoA and GlcN6P binding sites are different, some features are conserved, such as the highly conserved and critical tyrosine residue at position 127

(Tyr127), also present in nonapicomplexan GNA1 enzymes (29, 32, 33). At the level of the GlcN6P binding site, the main differences are localized in two arginine residues at positions 73 and 113, together with histidine, threonine, and glutamic acid residues at positions 81, 117, and 119, respectively. At the level of the acetyl-CoA binding site, the main differences are localized in histidine, asparagine, isoleucine, lysine, and leucine at positions 81, 90, 122, 125, and 126, respectively. Site-directed mutagenesis and kinetic assays confirmed the essential function of Tyr127. Likewise, GNA1 activity was not detected in our R141A mutant, suggesting that the positive charge of the arginine, which is also conserved in *HsGNA1*, might interact with the negatively charged atoms on the phosphate group of GlcN6P or facilitate the interaction of Arg113 with the phosphate group. Furthermore, our analyses showed that Arg73 and Arg113 residues are relevant for GlcN6P affinity, whereas His81 is important for both GlcN6P and acetyl-CoA binding, in agreement with our structural data showing that His81 interacts with both ligands. Although our data reveal that Thr117 is important for GlcN6P and acetyl-CoA binding, the latest is not completely understood because this residue only interacts with the sugar moiety. Overall, there are remarkable differences between *CpGNA1* and *HsGNA1* at the level of GlcN6P and acetyl-CoA binding sites, which could be exploited for drug selectivity against parasites.

The amino sugar pathway has been explored in different organisms as a possible source of novel therapeutic targets, and inhibitors of the *Aspergillus fumigatus* GNA1 enzyme have been recently identified (32, 33, 41). The independent evolution and sequence divergence of apicomplexan GNA1, together with its essentiality in *P. falciparum*, highlight the potential of the enzyme as a selective therapeutic target against the malaria parasite (10). Furthermore, the recent identification of the amino sugar pathway as an important metabolic bottleneck in *P. falciparum* indicates that the inhibition of *PfGNA1* could largely hamper the growth of the parasite (9). Remarkably, UDP-GlcNAc has also been reported as the most limiting sugar nucleotide in mosquito and liver stages, and, as stated above, several enzymes in the metabolic route have been proven to be essential for parasite transmission to mosquitoes in a malaria murine model (12). Altogether, the data underline the potential of *PfGNA1*, central to the amino sugar metabolic pathway, as a multistage drug target against *P. falciparum*. Interestingly, considering the particularities of GNA1 in the Apicomplexa and the importance of the UDP-GlcNAc donor for the biology of these organisms, the selective inhibition of the enzyme might also provide therapeutic opportunities against other apicomplexan pathogens such as *C. parvum* or *Toxoplasma gondii* (42, 43).

MATERIALS AND METHODS

***P. falciparum* culture and transfection.** *P. falciparum* asexual stages were cultured at 37°C in an atmosphere of 92% N₂, 3% O₂, and 5% CO₂ with washed B+ blood type red blood cells (RBCs) at 2 to 4% hematocrit in Albumax-containing RPMI 1640 medium. Human erythrocytes were purchased from the Banc de Sang i Teixits (Catalonia, Spain), after approval from the Comitè Ètic Investigació Clínica Hospital Clínic de Barcelona. Parasite growth was monitored by counting the infected erythrocytes in Giemsa-stained blood smears by light microscopy. Parasites harboring a floxed region of *gna1* were generated by Cas9-mediated gene replacement using a pDC2 Cas9- and specific-single guide RNA (sgRNA)-expressing construct, and a linearized pUC19 plasmid containing the engineered *gna1* sequence (19). *P. falciparum* 3D7 II-3 parasites, with the DiCre system inserted into the *p230p* genomic locus (a generous gift from Ellen Knuepfer [19]), were transfected during ring stages, as described elsewhere (37).

Parasites recovered after transfection were harvested for genotyping. Genomic DNA from parasites was extracted with the QIAmp DNA minikit (Qiagen) following the manufacturer's instructions. Purified samples were used as a template for PCR amplification of the inserted construct. Clonal parasite lines were then obtained from engineered populations by limiting dilution.

***P. falciparum* growth analysis.** For rapamycin treatment experiments, 0.1% DMSO or 10 nM rapamycin was added to the culture medium in ring-stage-synchronized parasites, incubated for 1 h, and washed away (19). This was done by adding 1:1,000 (vol/vol) stocks of 100% DMSO or 10 μM rapamycin, respectively, to the culture medium. Genomic DNA was recovered 24 to 30 h later. For growth assessment after rapamycin treatment, 200 μl of parasite culture at 3% hematocrit and with an initial parasitemia of 0.1% were transferred to 96-well plates. Parasitemia was assessed by flow cytometry after 48 h, 96 h, and 144 h, using SYTO11 as previously described (44).

Sugar nucleotide analysis. Asexual blood stage parasite cultures were sorbitol-synchronized (or combining Percoll and sorbitol treatments, for tight synchronization) and osmotic lysis was performed on trophozoite-infected red cells at 35 to 40 h postinvasion (5 to 10% parasitemia). Sugar nucleotides were

analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and multiple-reaction monitoring (MRM) in a QTRAP 6500 System (AB Sciex). The metabolites, separated using a Hypercarb PGC column (5 μm , 2.1×100 mm; Thermo Fisher Scientific) with a mobile phase composed of 0.1% formic acid (pH 9) and an acetonitrile gradient (24), were identified by their diagnostic MRM transitions (38).

Expression and purification of CpGNA1. The pGEX6P1-CpGNA1 plasmid encoding the CpGNA1 protein C terminus fused to the glutathione S-transferase (GST), with a PreScission Protease (PP) cleavage site (LEVLFGQP) encoded in the linker between GST and CpGNA1, was transformed into the *Escherichia coli* expression strain BL21 Star (Thermo Fisher Scientific). Transformants were selected on LB (Sigma-Aldrich) plates containing 100 $\mu\text{g}/\text{ml}$ of ampicillin. Batch cultures were scaled up to 2 liters of LB medium, and cells were grown to an optical density of 0.5 to 0.6 at 37°C and 180 rpm. They were subsequently induced with 1 mM isopropyl- β -D-thiogalactopyranoside (IPTG) (Sigma-Aldrich). After 20 h of induction at 18°C, the cells were collected by centrifugation at $11,295 \times g$ for 20 min. The resulting pellet was suspended in 60 ml of binding buffer A (25 mM TRIS [pH 7.5], 150 mM NaCl) that was supplemented with 4 μl of Universal Nuclease for Cell Lysis (Thermo Fisher Scientific, 250 U/ μl), lysozyme (Sigma-Aldrich, >95% pure) up to a final concentration of 1 mg/ml, and 500 μl of a protease-inhibitor cocktail solution (1 M PMSF, 10 mM benzamidine, 0.5 mM leupeptine). This solution was incubated for 30 min at 37°C and then sonicated in ice for 15 cycles, each consisting of a 30-s pulse plus a 30-s cooling step. The lysate was afterward centrifuged at $39,086 \times g$ for 20 min.

The supernatant was filtered through a 0.45- μm membrane and loaded at 1 ml/min into two connected GSTrap 4B (GE Healthcare) columns, previously equilibrated with buffer A. The columns were washed with buffer A until no 280-nm absorbance was observed, and the bound protein was eluted by a 25-min gradient from buffer A to buffer B (25 mM TRIS, 150 mM NaCl, 400 mM L-glutathione reduced [Sigma-Aldrich] [pH 7.5]). The recombinant fusion protein containing CpGNA1 was then exchanged into buffer C (25 mM Tris [pH 7.5], 150 mM NaCl) and incubated overnight at 4°C with PP at a ratio of 1 mg of PP per 50 mg of fusion protein, in order to remove the GST protein, leaving the GPLGS amino acids at the CpGNA1 N terminus. Once the cleavage was verified by SDS-PAGE, the mixture was loaded into three coupled GSTrap 4B columns, previously equilibrated in buffer A. Both GST and PP remained fixed to the column matrices, and the CpGNA1 was collected as the unbinding fraction. CpGNA1 was finally purified by size exclusion chromatography using a HiLoad 26/60 Superdex 75 Column (GE Healthcare), previously equilibrated with buffer C. Fractions containing CpGNA1 were dialyzed against buffer D (25 mM Tris pH 7.5), concentrated, and used for biophysical experiments. Quantification of the enzyme was carried out by absorbance at 280 nm using its theoretical extinction coefficient. A yield of 15 mg/liter of culture was obtained.

CpGNA1 crystallization, phasing, and refinement. Crystal forms for CpGNA1 were obtained when CpGNA1 (1.5 mg/ml) was cocrystallized with 10 mM acetyl-CoA. The sitting-drop vapor-diffusion method was used to produce crystals by mixing 0.5 μl of the protein-ligand solution with an equal volume of mother liquor (0.2 M NH_4Cl , 0.1 M HEPES [pH 7.5], 25% glycerolethoxilate) at 18°C. Bar-like-shaped crystals grew within 1 day. The crystals were soaked for 45 min with a mixture containing 50 mM acetyl-CoA and 50 mM Glc6P in the mother liquor described above. Then, crystals that were either cocrystallized with acetyl-CoA or further soaked with acetyl-CoA and Glc6P were cryoprotected using 25% glycerol in the mother liquor and frozen in nitrogen gas stream cooled to 100 K. X-ray diffraction data were collected at XALOC-13 beamline at ALBA Synchrotron. Data were processed and scaled using XDS (45) and CCP4 (46, 47) software packages. Relevant statistics are given in Table S1 in the supplemental material.

A promising partial solution for the monomeric CpGNA1 was identified for the P2₁2₁2 crystal form (crystals cocrystallized with acetyl-CoA) from a data set diffracting anisotropically to 1.5 Å, using the multisolution parallel phasing software ARCIMBOLDO_LITE (48). ARCIMBOLDO uses PHASER to place individual α -helices by eLLG-guided molecular replacement (49) and then expand partial solutions with SHELXE (50) through density modification and autotracing. The search was set to locate 1 copy of an ensemble generated with an alpha version of the software ALEPH (51). The ensemble of two models represented the probable fold composed by 5 beta strands flanked by 2 alpha helices at each side and it contained the GNA1 of *Saccharomyces cerevisiae* (PDB id 1I21, 19% identity to target sequence) and the acetyltransferase from *Agrobacterium tumefaciens* (PDB 2DXQ, 26% identity to target sequence). The ARCIMBOLDO_LITE solution was completed by SEQUENCE SLIDER (26) using side chain modeling with Scwrl4 (52), refinement with REFMAC5 (53), and expansion with SHELXE, resulting in a best trace of 120 residues with CC 31.9. The structure of CpGNA1 with the substrates at 1.95 Å, in space group P2₁2₁2₁, containing two monomers in the asymmetric unit was phased by molecular replacement (27) using the previous model. Initial phases were further improved by cycles of manual model building in Coot (54) and refinement with REFMAC5 (53) and Phenix (55). Further rounds of Coot and refinement with Phenix (55) were performed to obtain the final structure. The final model was validated with PROCHECK, and model statistics are given in Table S1. The Ramachandran plots for the CpGNA1-acetyl-CoA-Glc6P show that 89.0%, 10.6%, 0.4%, and 0% of the amino acids are in most favored, allowed, generously allowed, and disallowed regions, respectively. PyMOL (56) was used to generate images.

CpGNA1 colorimetric in vitro enzyme kinetic assays. Codon-optimized versions of CpGNA1 WT and site-specific mutant proteins were expressed and purified as previously described (10). Briefly, sequences were cloned in a pGEX 6P-1 vector containing an N-terminal GST-tag. After induction, fusion proteins were purified by affinity chromatography and eluted with reduced glutathione without cleaving the GST-tag. In vitro activity colorimetric assays were based on the detection of coenzyme A, generated during acetyl transfer, by reaction with the thiol reagent 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB). Acetyl-CoA and GlcN-6P were used as the substrates and all the reactions were carried out at room

temperature, in triplicate, in a 96-well-plate format. CpGNA1 was assayed in buffer solution (25 mM Tris-HCl and 150 mM NaCl, pH 7.2) using different acetyl-CoA concentrations and a fixed GlcN-6P concentration (2,000 μ M), or different GlcN-6P concentrations and a fixed acetyl-CoA concentration (500 μ M). CpGNA1 WT was assayed at a 5 μ g/ml concentration whereas CpGNA1 mutants were tested at a 25 μ g/ml concentration. The data were fitted to a nonlinear least-squares regression using GraphPad Prism.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, PDF file, 0.5 MB.

FIG S2, PDF file, 2 MB.

FIG S3, PDF file, 1 MB.

TABLE S1, DOCX file, 0.02 MB.

ACKNOWLEDGMENTS

We acknowledge support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria, which is partially supported by the Fundació Ramón Areces.

The authors would like to especially thank Ellen Knuepfer for the *P. falciparum* line 3D7 II.3. We are most grateful to M. Ramírez and the staff at the Separation Techniques core facility CCiTUB (Scientific and Technological Centers Universitat de Barcelona).

J.C. and M.C. were supported by an SAF2016-76080-R grant from the Spanish Ministry of Economy (AEI/FEDER, UE) to L. I. Research has also received funding from a Spanish Ministry of Science & Innovation grant PID2019-110810RB-I00 to L.I. L.I. and M.C. are members of the GlycoPar-EU FP7- funded Marie Curie Initial Training Network (GA 608295). I.U. was supported by grants PGC2018-101370-B-I00 and MDM2014-0435-01 from the Spanish Ministry of Science and Innovation and EU FEDER funds. A.M. was supported by fellowship BES-2017-080368 from the Spanish Ministry of Science and Innovation and R.J.B. was supported by a FAPESP 2016/24191-8 grant. R. H.-G. acknowledges ALBA Light Source (Barcelona, Spain) synchrotron beamline XALOC. He also acknowledges ARAID, MEC (CTQ2013-44367-C2-2-P, BFU2016-75633-P and PID2019-105451GB-I00) and Gobierno de Aragón (E34_R17 and LMP58_18) with FEDER (2014–2020) funds for “Building Europe from Aragón” for financial support. The research leading to these results has also received funding from FP7 442 (2007–2013) under BioStruct-X (grant agreement no. 283570 and BIOSTRUCTX_5186). A.P. acknowledges grant GLYCOZYMES (BFU2016-77427) from MICINN and P.L. acknowledges funds from URL/“Obra Social la Caixa.”

REFERENCES

- World Health Organization. 2020. WHO | World malaria report 2019. World Health Organization, Geneva, Switzerland. <https://www.who.int/publications/i/item/world-malaria-report-2019>.
- World Health Organization. 2018. WHO | World malaria report 2017. World Health Organization, Geneva, Switzerland. <https://www.who.int/malaria/publications/world-malaria-report-2017/report/en/>.
- Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han K-T, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Tracking Resistance to Artemisinin Collaboration (TRAC), et al. 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. *N Engl J Med* 371:411–423. <https://doi.org/10.1056/NEJMoa1314981>.
- Blasco B, Leroy D, Fidock DA. 2017. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. *Nat Med* 23: 917–928. <https://doi.org/10.1038/nm.4381>.
- WHO Strategic Advisory Group on Malaria Eradication. 2019. Malaria eradication: benefits, future scenarios and feasibility. Executive summary. World Health Organization, Geneva, Switzerland. (WHO/CDS/GMP/2019.10).
- Feachem RGA, Chen I, Akbari O, Bertozzi-Villa A, Bhatt S, Binka F, Boni MF, Buckee C, Dieleman J, Dondorp A, Eapen A, Sekhri Feachem N, Filler S, Gething P, Gosling R, Haakenstad A, Harvard K, Hatefi A, Jamison D, Jones KE, Karema C, Kamwi RN, Lal A, Larson E, Lees M, Lobo NF, Micah AE, Moonen B, Newby G, Ning X, Pate M, Quiñones M, Roh M, Rolfe B, Shanks D, Singh B, Staley K, Tulloch J, Wegbreit J, Woo HJ, Mpanju-Shumbusho W. 2019. Malaria eradication within a generation: ambitious, achievable, and necessary. *Lancet* 394:1056–1112. [https://doi.org/10.1016/S0140-6736\(19\)31139-0](https://doi.org/10.1016/S0140-6736(19)31139-0).
- Cowman AF, Healer J, Marapana D, Marsh K. 2016. Malaria: biology and disease. *Cell* 167:610–624. <https://doi.org/10.1016/j.cell.2016.07.055>.
- Burrows JN, Duparc S, Gutteridge WE, Hooft Van Huijsduijnen R, Kaszubska W, Macintyre F, Mazzuri S, Möhrle JJ, Wells TNC. 2017. New devel-

- opments in anti-malarial target candidate and product profiles. *Malar J* 16:26. <https://doi.org/10.1186/s12936-016-1675-x>.
9. Chiappino-Pepe A, Tymoshenko S, Ataman M, Soldati-Favre D, Hatzimanikatis V. 2017. Bioenergetics-based modeling of *Plasmodium falciparum* metabolism reveals its essential genes, nutritional requirements, and thermodynamic bottlenecks. *PLoS Comput Biol* 13:e1005397. <https://doi.org/10.1371/journal.pcbi.1005397>.
 10. Cova M, López-Gutiérrez B, Artigas-Jerónimo S, González-Díaz A, Bandini G, Maere S, Carretero-Paulet L, Izquierdo L. 2018. The Apicomplexa-specific glucosamine-6-phosphate N-acetyltransferase gene family encodes a key enzyme for glycoconjugate synthesis with potential as therapeutic target. *Sci Rep* 8:4005. <https://doi.org/10.1038/s41598-018-22441-3>.
 11. Zhang M, Wang C, Otto TD, Oberstaller J, Liao X, Adapa SR, Udenze K, Bronner IF, Casandra D, Mayho M, Brown J, Li S, Swanson J, Rayner JC, Jiang RHY, Adams JH. 2018. Uncovering the essential genes of the human malaria parasite *Plasmodium falciparum* by saturation mutagenesis. *Science* 360:eaap7847. <https://doi.org/10.1126/science.aap7847>.
 12. Stanway RR, Bushell E, Chiappino-Pepe A, Roques M, Sanderson T, Franke-Fayard B, Caldelari R, Golomingi M, Nyonda M, Pandey V, Schwach F, Chevalley S, Ramesar J, Metcalf T, Herd C, Burda PC, Rayner JC, Soldati-Favre D, Janse CJ, Hatzimanikatis V, Billker O, Heussler VT. 2019. Genome-scale identification of essential metabolic processes for targeting the *Plasmodium* liver stage. *Cell* 179:1112–1128.e26. <https://doi.org/10.1016/j.cell.2019.10.030>.
 13. Cova M, Rodrigues JA, Smith TK, Izquierdo L. 2015. Sugar activation and glycosylation in *Plasmodium*. *Malar J* 14:427. <https://doi.org/10.1186/s12936-015-0949-z>.
 14. Sanders PR, Kats LM, Drew DR, O'Donnell RA, O'Neill M, Maier AG, Coppel RL, Crabb BS. 2006. A set of glycosylphosphatidyl inositol-anchored membrane proteins of *Plasmodium falciparum* is refractory to genetic deletion. *Infect Immun* 74:4330–4338. <https://doi.org/10.1128/IAI.00054-06>.
 15. MacRae JI, Lopatnicki S, Maier AG, Rupasinghe T, Nahid A, Cowman AF, McConville MJ. 2014. *Plasmodium falciparum* is dependent on de novo myo-inositol biosynthesis for assembly of GPI glycolipids and infectivity. *Mol Microbiol* 91:762–776. <https://doi.org/10.1111/mmi.12496>.
 16. Rodrigues JA, Acosta-Serrano A, Aebi M, Ferguson MAJ, Routier FH, Schiller I, Soares S, Spencer D, Titz A, Wilson IBH, Izquierdo L. 2015. Parasite glycobiology: a bittersweet symphony. *PLoS Pathog* 11:e1005169. <https://doi.org/10.1371/journal.ppat.1005169>.
 17. Ferguson MA. 1999. The structure, biosynthesis and functions of glycosylphosphatidylinositol anchors, and the contributions of trypanosome research. *J Cell Sci* 112:2799–2809.
 18. Ginsburg H. 2006. Progress in in silico functional genomics: the malaria Metabolic Pathways database. *Trends Parasitol* 22:238–240. <https://doi.org/10.1016/j.pt.2006.04.008>.
 19. Knuepfer E, Napiorkowska M, van Ooij C, Holder AA. 2017. Generating conditional gene knockouts in *Plasmodium*—a toolkit to produce stable DiCre recombinase-expressing parasite lines using CRISPR/Cas9. *Sci Rep* 7:3881. <https://doi.org/10.1038/s41598-017-03984-3>.
 20. Ghorbal M, Gorman M, Macpherson CR, Martins RM, Scherf A, Lopez-Rubio J-J. 2014. Genome editing in the human malaria parasite *Plasmodium falciparum* using the CRISPR-Cas9 system. *Nat Biotechnol* 32:819–821. <https://doi.org/10.1038/nbt.2925>.
 21. Jones ML, Das S, Belda H, Collins CR, Blackman MJ, Treeck M. 2016. A versatile strategy for rapid conditional genome engineering using loxP sites in a small synthetic intron in *Plasmodium falciparum*. *Sci Rep* 6:21800. <https://doi.org/10.1038/srep21800>.
 22. Dyda F, Klein DC, Hickman AB. 2000. GCN5-related N-acetyltransferases: a structural overview. *Annu Rev Biophys Biomol Struct* 29:81–103. <https://doi.org/10.1146/annurev.biophys.29.1.81>.
 23. Vetting MW, S de Carvalho LP, Yu M, Hegde SS, Magnet S, Roderick SL, Blanchard JS. 2005. Structure and functions of the GNAT superfamily of acetyltransferases. *Arch Biochem Biophys* 433:212–226. <https://doi.org/10.1016/j.abb.2004.09.003>.
 24. López-Gutiérrez B, Dinglasan RR, Izquierdo L. 2017. Sugar nucleotide quantification by liquid chromatography tandem mass spectrometry reveals a distinct profile in *Plasmodium falciparum* sexual stage parasites. *Biochem J* 474:897–905. <https://doi.org/10.1042/BJC20161030>.
 25. Rodríguez D, Sammito M, Meindl K, De Ilarduya JM, Potratz M, Sheldrick GM, Usón I. 2012. Practical structure solution with ARCIMBOLDO. *Acta Crystallogr D Biol Crystallogr* 68:336–343. <https://doi.org/10.1107/S0907444911056071>.
 26. Borges RJ, Meindl K, Triviño J, Sammito M, Medina A, Millán C, Alcorlo M, Hermoso JA, Fontes MRDM, Usón I. 2020. SEQUENCE SLIDER: expanding polyaniline fragments for phasing with multiple side-chain hypotheses. *Acta Crystallogr D Struct Biol* 76:221–237. <https://doi.org/10.1107/S2059798320000339>.
 27. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. *J Appl Crystallogr* 40:658–674. <https://doi.org/10.1107/S0021889807021206>.
 28. Hurtado-Guerrero R, Raimi O, Shepherd S, van Aalten DMF. 2007. Glucose-6-phosphate as a probe for the glucosamine-6-phosphate N-acetyltransferase Michaelis complex. *FEBS Lett* 581:5597–5600. <https://doi.org/10.1016/j.febslet.2007.10.065>.
 29. Wang J, Liu X, Liang Y-H, Li L-F, Su X-D. 2008. Acceptor substrate binding revealed by crystal structure of human glucosamine-6-phosphate N-acetyltransferase 1. *FEBS Lett* 582:2973–2978. <https://doi.org/10.1016/j.febslet.2008.07.040>.
 30. Peneff C, Mengin-Lecreux D, Bourne Y. 2001. The crystal structures of Apo and complexed *Saccharomyces cerevisiae* GNA1 shed light on the catalytic mechanism of an amino-sugar N-acetyltransferase. *J Biol Chem* 276:16328–16334. <https://doi.org/10.1074/jbc.M009988200>.
 31. Milewski S, Gabriel I, Olchoway J. 2006. Enzymes of UDP-GlcNAc biosynthesis in yeast. *Yeast* 23:1–14. <https://doi.org/10.1002/yea.1337>.
 32. Hurtado-Guerrero R, Raimi OG, Min J, Zeng H, Vallius L, Shepherd S, Ibrahim AFM, Wu H, Plotnikov AN, van Aalten DMF. 2008. Structural and kinetic differences between human and *Aspergillus fumigatus* D-glucosamine-6-phosphate N-acetyltransferase. *Biochem J* 415:217–223. <https://doi.org/10.1042/BJ20081000>.
 33. Mariño K, Güther MLS, Wernimont AK, Qiu W, Hui R, Ferguson MAJ. 2011. Characterization, localization, essentiality, and high-resolution crystal structure of glucosamine 6-phosphate N-acetyltransferase from *Trypanosoma brucei*. *Eukaryot Cell* 10:985–997. <https://doi.org/10.1128/EC.05025-11>.
 34. Srivastava P, Khandokar YB, Swarbrick CMD, Roman N, Himiari Z, Sarker S, Raidal SR, Forwood JK. 2014. Structural characterization of a Gcn5-related N-Acetyltransferase from *Staphylococcus aureus*. *PLoS One* 9:e102348. <https://doi.org/10.1371/journal.pone.0102348>.
 35. Collins CR, Das S, Wong EH, Andenmatten N, Stallmach R, Hackett F, Herman J-P, Müller S, Meissner M, Blackman MJ. 2013. Robust inducible Cre recombinase activity in the human malaria parasite *Plasmodium falciparum* enables efficient gene deletion within a single asexual erythrocytic growth cycle. *Mol Microbiol* 88:687–701. <https://doi.org/10.1111/mmi.12206>.
 36. Bushell E, Gomes AR, Sanderson T, Anar B, Girling G, Herd C, Metcalf T, Modrzynska K, Schwach F, Martin RE, Mather JW, McFadden GI, Parts L, Rutledge GG, Vaidya AB, Wengelnik K, Rayner JC, Billker O. 2017. Functional profiling of a *Plasmodium* genome reveals an abundance of essential genes. *Cell* 170:260–272. <https://doi.org/10.1016/j.cell.2017.06.030>.
 37. Sanz S, López-Gutiérrez B, Bandini G, Damerow S, Absalon S, Dinglasan RR, Samuelson J, Izquierdo L. 2016. The disruption of GDP-fucose de novo biosynthesis suggests the presence of a novel fucose-containing glycoconjugate in *Plasmodium* asexual blood stages. *Sci Rep* 6:37230. <https://doi.org/10.1038/srep37230>.
 38. Sanz S, Bandini G, Ospina D, Bernabeu M, Mariño K, Fernández-Becerra C, Izquierdo L. 2013. Biosynthesis of GDP-fucose and other sugar nucleotides in the blood stages of *Plasmodium falciparum*. *J Biol Chem* 288:16506–16517. <https://doi.org/10.1074/jbc.M112.439828>.
 39. Qureshi AA, Suades A, Matsuoka R, Brock J, McComas SE, Nji E, Orellana L, Claesson M, Delemotte L, Drew D. 2020. The molecular basis for sugar import in malaria parasites. *Nature* 578:321–325. <https://doi.org/10.1038/s41586-020-1963-z>.
 40. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS. 2011. The human serum metabolome. *PLoS One* 6:e16957. <https://doi.org/10.1371/journal.pone.0016957>.
 41. Lockhart DEA, Stanley M, Raimi OG, Robinson DA, Boldovjakova D, Squair DR, Ferenbach AT, Fang W, Van Aalten DMF. 2020. Targeting a critical step in fungal hexosamine biosynthesis. *J Biol Chem* 295:8678–8691. <https://doi.org/10.1074/jbc.RA120.012985>.
 42. Cevallos AM, Bhat N, Verdon R, Hamer DH, Stein B, Tzipori S, Pereira ME, Keusch GT, Ward HD. 2000. Mediation of *Cryptosporidium parvum* infection in vitro by mucin-like glycoproteins defined by a neutralizing

- monoclonal antibody. *Infect Immun* 68:5167–5175. <https://doi.org/10.1128/iai.68.9.5167-5175.2000>.
43. Krishnan A, Kloehn J, Lunghi M, Chiappino-Pepe A, Waldman BS, Nicolas D, Varesio E, Hehl A, Lourido S, Hatzimanikatis V, Soldati-Favre D. 2020. Functional and computational genomics reveal unprecedented flexibility in stage-specific *Toxoplasma* metabolism. *Cell Host Microbe* 27:290–306. <https://doi.org/10.1016/j.chom.2020.01.002>.
 44. Urbán P, Estelrich J, Cortés A, Fernández-Busquets X. 2011. A nanovector with complete discrimination for targeted delivery to *Plasmodium falciparum*-infected versus non-infected red blood cells in vitro. *J Control Release* 151:202–211. <https://doi.org/10.1016/j.jconrel.2011.01.001>.
 45. Kabsch W. 2010. XDS. *Acta Crystallogr D Biol Crystallogr* 66:125–132. <https://doi.org/10.1107/S0907444909047337>.
 46. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AGW, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. 2011. Overview of the CCP4 suite and current developments. *Acta Crystallogr D Biol Crystallogr* 67:235–242. <https://doi.org/10.1107/S0907444910045749>.
 47. Collaborative Computational Project. 1994. The CCP4 suite: programs for protein crystallography. *Acta Crystallogr Sect D Biol Crystallogr* 50:760–763. <https://doi.org/10.1107/S0907444994003112>.
 48. Sammito M, Millán C, Frieske D, Rodríguez-Freire E, Borges RJ, Usón I. 2015. ARCIMBOLDO_LITE: single-workstation implementation and use. *Acta Crystallogr D Biol Crystallogr* 71:1921–1930. <https://doi.org/10.1107/S1399004715010846>.
 49. Oeffner RD, Afonine PV, Millán C, Sammito M, Usón I, Read RJ, McCoy AJ. 2018. On the application of the expected log-likelihood gain to decision making in molecular replacement. *Acta Crystallogr D Struct Biol* 74:245–255. <https://doi.org/10.1107/S2059798318004357>.
 50. Usón I, Sheldrick GM. 2018. An introduction to experimental phasing of macromolecules illustrated by SHELX; new autotracing features. *Acta Crystallogr D Struct Biol* 74:106–116. <https://doi.org/10.1107/S2059798317015121>.
 51. Medina A, Triviño J, Borges RJ, Millán C, Usón I, Sammito MD. 2020. ALEPH: a network-oriented approach for the generation of fragment-based libraries and for structure interpretation. *Acta Crystallogr D Struct Biol* 76:193–208. <https://doi.org/10.1107/S2059798320001679>.
 52. Krivov GG, Shapovalov MV, Dunbrack RL. 2009. Improved prediction of protein side-chain conformations with SCWRL4. *Proteins Struct Funct Bioinforma* 77:778–795. <https://doi.org/10.1002/prot.22488>.
 53. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA. 2011. REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr D Biol Crystallogr* 67:355–367. <https://doi.org/10.1107/S0907444911001314>.
 54. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 60:2126–2132. <https://doi.org/10.1107/S0907444904019158>.
 55. Liebschner D, Afonine PV, Baker ML, Bunkoczi G, Chen VB, Croll TI, Hintze B, Hung LW, Jain S, McCoy AJ, Moriarty NW, Oeffner RD, Poon BK, Prisant MG, Read RJ, Richardson JS, Richardson DC, Sammito MD, Sobolev OV, Stockwell DH, Terwilliger TC, Urzhumtsev AG, Videau LL, Williams CJ, Adams PD. 2019. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. *Acta Crystallogr D Struct Biol* 75:861–877. <https://doi.org/10.1107/S2059798319011471>.
 56. DeLano WL. 2002. PyMOL: an open-source molecular graphics tool. *CCP4 Newsl Protein Crystallogr* 40:82–92. http://148.79.162.84/newsletters/newsletter40/11_pymol.pdf.